At a Glance
| Feature | Detail |
|---|---|
| Condition | Human Immunodeficiency Virus (HIV) |
| ICD-10 Code | B20 |
| CDL Status | YES — Chronic Disease List (CDL 017) |
| PMB Coverage | Full — ARV therapy funded at CDL level |
| SA Prevalence | ~7.9 million South Africans (12.3% of the population) |
| Standard Treatment | TLD (tenofovir/lamivudine/dolutegravir) — once daily |
| Private ARV Cost | ~R600/month (R7,200/year) |
| Annual Management Cost | ~R10,000–R42,000 depending on disease stage |
| Biologic Risk | No |
| Key Advisory Angle | ARVs are CDL-funded. The advisory decision is employer scheme access (GEMS, Polmed). |
About HIV
HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, specifically CD4+ T-cells, which coordinate the body's defence against infections. Without treatment, HIV can progress to AIDS (Acquired Immunodeficiency Syndrome), a stage of advanced immune suppression in which life-threatening opportunistic infections occur.
With modern antiretroviral therapy (ART), people living with HIV can achieve undetectable viral loads, near-normal life expectancy, and excellent quality of life. HIV is a manageable chronic condition — not a terminal diagnosis.
South Africa carries the world's largest HIV burden: 7.9 million people living with HIV as of mid-2025, with 6.18 million currently on antiretroviral treatment. SA also runs the world's largest public antiretroviral therapy programme.
How HIV Progresses
HIV infection follows three broad stages if untreated:
Stage 1 — Acute infection: Within 2–4 weeks of exposure, many people develop flu-like symptoms (fever, rash, swollen lymph nodes). This is the period of highest viral replication and the highest risk of transmission.
Stage 2 — Chronic infection (clinical latency): The virus continues replicating at lower levels. Most people have no symptoms for years. Without treatment, this stage lasts an average of 10 years, though it varies. CD4 count gradually declines.
Stage 3 — AIDS: When the CD4 count falls below 200 cells/μL (or an AIDS-defining illness occurs), a person is diagnosed with AIDS. At this stage, the immune system is severely compromised and opportunistic infections become life-threatening.
With treatment: ART prevents progression entirely. A person diagnosed with HIV today and started on treatment can expect to live a near-normal lifespan.
Monitoring and Diagnosis
| Test | Purpose | Frequency |
|---|---|---|
| HIV viral load (PCR) | Measure virus level in blood; target = undetectable (< 50 copies/mL) | 3–6 months after starting ART; annually once stable |
| CD4 count | Assess immune health | At initiation; 6 months; annually |
| Creatinine / eGFR | Monitor kidney function (TDF monitoring) | At initiation; annually |
| Hepatitis B surface antigen (HBsAg) | Screen for HBV co-infection at initiation | Once at initiation |
| Full blood count | General monitoring | Annually |
Treatment: South Africa's ARV Programme
South Africa adopted TLD — a fixed-dose combination of tenofovir disoproxil fumarate / lamivudine / dolutegravir (TDF/3TC/DTG) — as its preferred first-line ART regimen in 2019, replacing the previous efavirenz-based regimen. TLD offers superior tolerability, a high genetic barrier to resistance, and once-daily dosing.
First-line: TLD (one tablet, once daily) Alternative first-line: ALD (abacavir/lamivudine/dolutegravir) — for patients who cannot tolerate TDF (kidney disease, osteoporosis risk) Second-line: Protease inhibitor-based regimens (lopinavir/ritonavir) — for confirmed virological failure after adherence optimisation Third-line/complex: Darunavir-based or novel agents — specialist-managed
Annual Cost Estimates (Private Sector)
| Severity | Profile | Estimated Annual Cost |
|---|---|---|
| Well-controlled | TLD, stable viral load, 4 annual visits + labs | ~R10,000 |
| Adherence challenges | TLD, quarterly monitoring, viral load management | ~R12,000 |
| Late-stage / opportunistic infection | Second-line ART, specialist visits, OI treatment | R22,000–R42,000+ |
Note: Public sector ART is free via the Department of Health / Global Fund programme. Private sector figures above reflect medical aid-registered patients.
The PMB and CDL Position
HIV is a Chronic Disease List (CDL) condition under the Medical Schemes Act. All registered medical schemes must fund:
- First-line ART (TLD) and approved alternatives
- CD4 count and viral load monitoring (at CDL minimum frequency)
- Second-line ART on confirmed virological failure with specialist motivation
- Opportunistic infection treatment (as PMB)
What is NOT in the CDL formulary: - Advanced third-line ARV regimens (darunavir-based, novel agents) — require exceptional needs authorisation - PrEP (pre-exposure prophylaxis) — for HIV-negative individuals; generally not PMB-funded - Post-exposure prophylaxis (PEP) — scheme-dependent; check your specific plan - HIV testing initiated for non-diagnostic purposes — typically day-to-day benefits
Gap Cover Relevance
For well-controlled HIV on TLD with an undetectable viral load, gap cover is not a primary concern. All routine management is CDL-funded. The gap cover exposure arises if the immune system is compromised and opportunistic infections requiring specialist inpatient care occur.
| Scenario | Gap Cover Relevance |
|---|---|
| Well-controlled HIV (undetectable viral load) | LOW — CDL covers all routine management |
| Late-stage / low CD4 with opportunistic infection | HIGH — infectious disease specialist shortfalls; ICU if required |
| TB co-infection (hospitalised) | HIGH — respiratory specialist + infectious disease shortfall |
| Cryptococcal meningitis | VERY HIGH — neurologist + ICU + antifungal specialist |
The most important HIV financial advisory point is not gap cover selection — it is knowing your scheme's ARV dispensing network and CDL registration process.
The Talk to Eldon Angle
Your ARVs are fully CDL-covered. TLD — one tablet, once daily — costs approximately R600/month in the private sector. Your scheme must fund this. Annual private sector HIV management for well-controlled disease runs approximately R10,000 — dominated by GP visits and laboratory tests, not medication.
Employer scheme consideration: If you are a government employee (GEMS — Government Employees Medical Scheme) or a South African Police Service employee (Polmed), these restricted-membership schemes have dedicated HIV management programmes. For qualifying individuals, they may represent the best-structured HIV coverage in the sector.
Sources
- Spotlight NSP / Thembisa Model (March 2025). 8 million people living with HIV in SA. spotlight.co.za
- SAHCS 2023 Adult ART Guidelines. Southern African Journal of HIV Medicine, 2023.
- Daily Maverick (May 2026). SA's ARV programme growth stalls.
- CMS PMB Regulations — CDL: HIV and AIDS. medicalschemes.co.za
Ready to check your HIV cover? Run your AURA medical aid check